Abstract:Graphical and Lay Summary In this study, an artificial gene expression system was developed utilizing the chimeric protein Gal4‐ERT2‐VP16 (GEV), which becomes active upon exposure to estrogen receptor ligands. The system was designed for the inducible production of recombinant proteins in CHO cells. GEV acts as a transcriptional activator, triggering the expression of target genes upon the addition of estrogen, β‐estradiol (E2), or the E2 antagonist 4‐hydroxytamoxifen (4‐OHT) to the culture medium. This work demonstrates an efficient method for producing recombinant proteins, effectively separating the cell proliferation phase from the production phase. Biopharmaceuticals, including therapeutic antibodies, are rapidly growing products in the pharmaceutical market. Mammalian cells, such as Chinese hamster ovary (CHO) cells, are widely used as production hosts because recombinant antibodies require complex three‐dimensional structures modified with sugar chains. Recombinant protein production using mammalian cells is generally performed with cell growth. In this study, we developed a technology that controls cell growth and recombinant protein production to induce recombinant protein production with predetermined timing. Expression of green fluorescent protein (GFP) gene and a single‐chain antibody fused with the Fc‐region of the human IgG1 (scFv‐Fc) gene can be induced and mediated by the estrogen receptor‐based artificial transcription factor Gal4‐ERT2‐VP16 and corresponding inducer drugs. We generated CHO cells using an artificial gene expression system. The addition of various concentrations of inducer drugs to the culture medium allowed control of proliferation and transgene expression of the engineered CHO cells. Use of 4‐hydroxytamoxifen, an antagonist of estrogen, as an inducing agent yielded high gene expression at a concentration more than 10‐fold lower than that of β‐estradiol. When scFv‐Fc was produced under inducing conditions, continuous production was possible for more than 2 weeks while maintaining high specific productivity (57 pg cell−1 day−1). This artificial gene expression control system that utilizes the estrogen response of estrogen receptors can be an effective method for inducible production of biopharmaceuticals.

Development of an Expression Vector Engineering Strategy Based on tDNA Insulator Element for the Stable Expression of Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein

Construction of A Lentiviral Vector Simultaneously Expressing Active IGF1, EGF and FGF2

Stabilizing and Anti-Repressor Elements Effectively Increases Transgene Expression in Transfected CHO Cells

Construction of novel conditional transgenic vectors for molecular therapy based on the Tet-On system and flanked with insulators in a single plasmid

Fusion of the Dhfr/Mtx and IR/MAR Gene Amplification Methods Produces a Rapid and Efficient Method for Stable Recombinant Protein Production

Generation of a Stable Mammalian Cell Line for Simultaneous Expression of Multiple Genes by Using 2A Peptide-Based Lentiviral Vector

Combination of FACS and Homologous Recombination for the Generation of Stable and High-Expression Engineered Cell Lines.

Expression of vascular endothelial growth factor in endothelial progenitor cells following its expression vector construction

Inducible transgene expression in CHO cells using an artificial transcriptional activator with estrogen‐binding domain

Regulatory elements in vectors containing the ctEF-1α first intron and double enhancers for an efficient recombinant protein expression system

Construction of a vascular endothelial growth factor and sodium iodide symporter gene co-expressing eukaryotic vector

Synthetic enhancers including TFREs improve transgene expression in CHO cells

Construction of Recombinant FGFR1 Containing Full-Length Gene and Its Potential Application

Enhanced Transgene Expression by Optimization of Poly A in Transfected CHO Cells

Optimization of a novel expression system for recombinant protein production in CHO cells

Current strategies for the development of high-yield HEK293 cell lines

The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor--an alternative gene therapy

Optimization of a transient antibody expression platform towards high titer and efficiency

Integrated cell and process engineering for improved transient production of a "difficult-to-express" fusion protein by CHO cells

Construction of a stable expression HEK293T engineered cell line adapted to high-density suspension culture

Construction of a Recombinant Human FGF1 Expression Vector for Mammary Gland-Specific Expression in Human Breast Cancer Cells